| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
Purity: ≥98%
Description: BI-671800 is a novel, potent and highly specific antagonist of chemoattractant receptor-homologous molecule on Th2 cells (DP2/CRTH2), with IC50 values of 4.5 nM and 3.7 nM for PGD2 binding to CRTH2 in hCRTH2 and mCRTH2 transfected cells, respectively. BI-671800 can be potentially used for the treatment of poorly controlled asthma.
| Targets |
Compound A (Cmpd A) is a potent and selective antagonist of the prostaglandin D₂ receptor–chemoattractant receptor-homologous molecule expressed on Tₕ₂ cells (CRTH2). The IC₅₀ values for inhibiting PGD₂ binding to CRTH2 are 3.7 nM for murine CRTH2 and 4.5 nM for human CRTH2. The IC₅₀ values for other prostanoid, thromboxane, or cysteinyl leukotriene receptors (DP1, BLT1, CysLT1, CysLT2, EP1, EP2, EP3, EP4, FP, IP, TP) are all >10 μM. Additionally, Cmpd A showed no activity on a broad panel of G protein-coupled receptors in a screening assay. [1]
|
|---|---|
| ln Vitro |
In transfected cells, BI-671800 (Compound A) has modest nM efficacy as a human or mouse CRTH2 antagonist [1].
Cmpd A down-regulated the transcription of a wide range of pro-inflammatory genes in FITC-challenged mouse ears, including cytokines (IL-1β, IL-4, IL-13), chemokines (CCL7/MCP-3, CCL4/MIP-1β, CXCL9/MIG), and atopy-associated genes (mucin-1, trefoil factors 1–3). [1] |
| ln Vivo |
BI-671800 (compound A, 0.1-10 mg/kg, ig) has a strong inhibitory effect on mice AHR [1]. BI-671800 (Compound A) substantially inhibits edema formation and greatly lowers inflammatory infiltrates and skin pathology observed in drug vehicle-treated mice [3].
In a FITC-induced allergic contact hypersensitivity model in BALB/c mice, oral administration of Cmpd A (0.1, 1, or 10 mg/kg) significantly inhibited ear swelling in a dose-dependent manner, with peak inhibition observed at 10 mg/kg. Histological analysis showed reduced leukocyte infiltration (lymphocytes, eosinophils, neutrophils) and absence of epidermal microabscesses in treated mice. Cmpd A also reduced protein levels of pro-inflammatory cytokines (IL-4, TNF-α, TGF-β) and chemokines (MIP-2, GRO-α) in challenged ears. [1] |
| Enzyme Assay |
A radioligand binding assay was performed to characterize Compound A. CRTH2-transfected cells were suspended in binding buffer. Cell suspensions were incubated with tritiated PGD₂ and varying concentrations of the test compound for 1 hour at room temperature. After incubation, the mixtures were transferred to filtration plates, washed, and the bound radioactivity was measured using a scintillation counter. Competition binding curves were analyzed to determine IC₅₀ values. [3]
A separate panel screening for binding affinity against a broad set of prostanoid, thromboxane, and cysteinyl leukotriene receptors was conducted using standard protocols. [3] |
| Cell Assay |
Protein lysates from FITC-challenged mouse ears were analyzed by ELISA for cytokine and chemokine levels. Ears were homogenized in protein isolation buffer with protease and phosphatase inhibitors, centrifuged to remove debris, and supernatants were quantified for total protein. Cytokine/chemokine levels were measured using commercial ELISA kits according to the manufacturer’s protocols. [1]
|
| Animal Protocol |
Animal/Disease Models: 6-8 weeks old, age- and sex-matched balb/c (Bagg ALBino) mouse (mouse sensitized for 14 days, intranasally challenged) [1].
Doses: 10-0.1 mg/kg Route of Administration: po (oral gavage) for 4 weeks. Experimental Results: It has a significant inhibitory effect on AHR in mice. A 1-week acute FITC-induced allergic inflammation model was used. Female BALB/c mice were shaved on the belly and sensitized with 0.5% FITC solution on days 1 and 2. On day 6, mice were challenged with 0.5% FITC on the right ear and vehicle on the left ear. Cmpd A was administered orally 1 hour before challenge and again 7 hours post-challenge. Ear thickness was measured at various time points using digital calipers. For cytokine analysis, ears were harvested, snap-frozen, homogenized, and protein lysates were prepared for ELISA. [1] |
| References |
|
| Additional Infomation |
Bi 671800 has been used in a trial to investigate the treatment of asthma and allergic perennial rhinitis. Compound A is a proprietary small molecule CRTH2 antagonist developed by Actimis Pharmaceuticals. In a FITC-induced contact hypersensitivity model, CRTH2 antagonism inhibited the production of multiple inflammatory pathways, including TSLP and IL-1β, and reduced the recruitment of neutrophils and eosinophils. This study suggests that CRTH2 antagonism may be a potential strategy for treating allergic skin conditions such as atopic dermatitis. [1]
|
| Molecular Formula |
C25H26F3N5O3
|
|---|---|
| Molecular Weight |
501.500855922699
|
| Exact Mass |
501.199
|
| Elemental Analysis |
C, 59.87; H, 5.23; F, 11.36; N, 13.96; O, 9.57
|
| CAS # |
1093108-50-9
|
| PubChem CID |
45270144
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.481
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
36
|
| Complexity |
717
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
FC(C1C=CC(=CC=1)C(NC1C=CC(=CC=1)CC1=NC(=C(CC(=O)O)C(=N1)N(C)C)N(C)C)=O)(F)F
|
| InChi Key |
XEOSTBFUCNZKGS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C25H26F3N5O3/c1-32(2)22-19(14-21(34)35)23(33(3)4)31-20(30-22)13-15-5-11-18(12-6-15)29-24(36)16-7-9-17(10-8-16)25(26,27)28/h5-12H,13-14H2,1-4H3,(H,29,36)(H,34,35)
|
| Chemical Name |
5-Pyrimidineacetic acid, 4,6-bis(dimethylamino)-2-((4-((4-(trifluoromethyl)benzoyl)amino)phenyl)methyl)-
|
| Synonyms |
BI-671800; BI 671800; BI671800.
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~135 mg/mL (~269.19 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.25 mg/mL (4.49 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 22.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.25 mg/mL (4.49 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 22.5 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9940 mL | 9.9701 mL | 19.9402 mL | |
| 5 mM | 0.3988 mL | 1.9940 mL | 3.9880 mL | |
| 10 mM | 0.1994 mL | 0.9970 mL | 1.9940 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA